Edesa Biotech, Inc.
(NASDAQ : EDSA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. -0.96%92.131.9%$1145.22m
JNJJohnson & Johnson -0.87%144.440.7%$1085.68m
BMYBristol-Myers Squibb Co. -0.57%60.791.0%$940.95m
PFEPfizer Inc. 0.64%37.500.9%$816.71m
MRKMerck & Co., Inc. -0.22%76.380.7%$776.51m
LLYEli Lilly & Co. -0.69%151.231.1%$447.35m
AZNAstraZeneca Plc -0.11%55.221.2%$249.77m
NVSNovartis AG -0.09%84.910.2%$158.95m
GSKGlaxoSmithKline Plc -0.37%40.880.2%$141.36m
BHCBausch Health Cos., Inc. -2.26%17.770.0%$113.04m
SNYSanofi -0.30%47.300.2%$86.66m
NVONovo Nordisk A/S 0.05%64.850.1%$84.91m
RGENRepligen Corp. -0.57%139.517.1%$72.80m
ARCTArcturus Therapeutics Holdings, Inc. 7.71%58.270.0%$57.13m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 11.80%58.370.0%$43.19m

Company Profile

Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.